Recalibrating PTSD Screening and Prediction: A Pragmatic Agenda to Reduce Missed Cases, False Alarms and Model Hype

Post-traumatic stress disorder (PTSD) screening and prediction tools are widely used in veteran and trauma-exposed populations, yet methodological practices show substantial gaps. Rigid threshold application, inconsistent calibration reporting and limited attention to sex-based performance differences, comorbid conditions including traumatic brain injury (TBI) and moral injury and cultural context may introduce inequities and reduce clinical utility.

PTSD screening programmes miss cases in some groups while over-referring in others, yet lack practical guidance for addressing these disparities. We provide an implementation framework that operationalizes existing standards (TRIPOD-AI, PROBAST-AI) with concrete, PTSD-specific procedures for calibration assessment, sex-stratified analysis and comorbidity integration.

We conducted a systematic scoping review of PTSD screening and prediction studies (2019-2024, n = 75 studies) and synthesized published meta-analytic evidence on TBI-PTSD associations as a worked exemplar of comorbidity integration. We developed a tiered implementation framework (Tier 1: minimum standards; Tier 2: recommended practices; Tier 3: excellence standards) addressing observed heterogeneity. Technical feasibility was demonstrated using synthetic data explicitly matching published PTSD parameters from landmark veteran studies.

The scoping review of 75 studies (2019-2024) found that only three studies (4.0%) reported calibration metrics, and only 10.7% provided sex-disaggregated performance metrics. Current reporting practices inadequately address TBI-PTSD comorbidity heterogeneity, moral injury (0% of studies) and cultural adaptation. These findings document substantial methodological gaps and demonstrate framework recommendations target empirically observed heterogeneity. The framework organizes recommendations into three tiers based on feasibility and resource requirements. Tier 1 standards (achievable by all studies) include: precise population definition, pre-specified thresholds, calibration slope reporting, sex-disaggregated performance and missing data documentation. Tier 2 recommendations (feasible for most studies) include: bootstrap internal validation, formal sex-stratified calibration testing with specified interaction thresholds (|β₃| > 0.10), decision curve analysis, comorbidity integration and multiple imputation (m ≥ 20). Tier 3 excellence standards (aspirational for well-resourced studies) include: rigorous multi-site external validation, annual calibration monitoring and cultural adaptation for refugee contexts. Synthetic data demonstration (n = 850, matching Bovin 2016 and Wortmann 2016 published parameters: PTSD prevalence = 33%, PCL-5 distributions, TBI prevalence = 35%) confirmed technical feasibility using standard statistical software. Bootstrap validation (500 iterations) yielded optimism-corrected AUC = 0.969 with negligible optimism. Sex-stratified analysis detected meaningful calibration differences (|Δ| = 0.14, exceeding threshold). Comorbidity analysis revealed prevalence stratification (40.4% vs. 30.6%) despite minimal discrimination improvement (ΔAUC = +0.003), clarifying comorbidity's dual role in prediction versus case-finding.

Published meta-analyses demonstrate consistent TBI-PTSD associations (2.68× risk overall; 4.18× in military populations) alongside substantial prevalence heterogeneity (I² = 96%) that current reporting practices inadequately address. Using TBI as a worked exemplar of comorbidity integration alongside sex-stratified validation, moral injury assessment and cultural adaptation, the tiered framework provides PTSD-specific operational guidance for implementing established methodological standards, designed for incremental adoption based on study resources. All Tier 2 components are implementable with standard methods and moderate sample sizes. Prospective validation studies are needed to assess whether framework implementation improves calibration stability, subgroup equity and clinical outcomes compared to standard practice.